BTIG Maintains Buy on Legend Biotech, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin maintains a Buy rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $85 to $90.
June 13, 2023 | 3:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Justin Zelin maintains a Buy rating on Legend Biotech and raises the price target from $85 to $90.
The news of BTIG maintaining a Buy rating and raising the price target for Legend Biotech is positive for the company's stock. This indicates that the analyst has a positive outlook on the company's performance and growth potential, which could lead to an increase in demand for the stock and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100